Why Weight Loss is the First Treatment for Idiopathic Intracranial Hypertension
Characterized by elevated intracranial pressure (ICP) and symptoms like persistent headaches, visual changes, and pulsatile tinnitus, IIH mostly affects women of childbearing age who are overweight or obese. These groups are at higher risk, and risk factors include obesity and recent weight gain. Vision problems are among the most important clinical features of IIH.
While the exact cause remains elusive, the condition is idiopathic, meaning there is no known cause, despite the presence of risk factors and a clear clinical presentation. One thing is clear: weight loss isn't just helpful—it's essential. It's the only intervention proven to modify the disease course, offering relief from symptoms and a protective effect against vision loss [1] [4].
At its core, IIH is defined by increased pressure inside the skull without a detectable cause, such as a mass or hydrocephalus. Diagnostic criteria for IIH include clinical features, brain imaging to rule out an intracranial mass, and measurement of cerebrospinal fluid pressure via lumbar puncture (spinal tap). Patients often present with:
Other symptoms can include neck or back pain, dizziness, and cognitive changes.
Though the mechanisms aren't fully understood, there's a well-established link between IIH and obesity. The theory is that excess body weight may impair venous drainage from the brain, leading to cerebrospinal fluid (called cerebrospinal fluid) buildup around the brain and spinal cord. Venous sinus stenosis and abnormal venous pressure may contribute to increased intracranial pressure in IIH. This connection is why weight reduction remains the foundation of treatment [1] [4].
IIH occurs most often in women of childbearing age, but can affect others as well.
The 2018 Consensus Guidelines published in the Journal of Neurology, Neurosurgery & Psychiatry make it unequivocally clear: weight loss is the most effective strategy for managing IIH [1] [4]. Even a modest reduction in weight—just 5% to 10% of a person's total body weight—has been shown to significantly decrease intracranial pressure, relieve headaches, and improve vision [5]. Women who are more than 20% above their ideal body weight are at increased risk for IIH, so losing weight to reach or approach ideal body weight is a key goal in management.
Weight loss isn't a one-size-fits-all recommendation. It's a structured, multidisciplinary effort that often involves:
For patients with a BMI over 30 kg/m², early intervention is critical. Experts recommend a compassionate, consistent approach that respects the psychosocial complexities of weight and body image [1].
Acetazolamide is typically the first drug prescribed. It works by inhibiting carbonic anhydrase, which reduces the production of CSF.
Topiramate offers a double advantage. It not only lowers CSF production but also helps with weight loss—a bonus in IIH management.
Surgery is usually a last resort, reserved for patients who have:
Surgical options include:
Each of these procedures carries potential risks, so decisions should be made in consultation with neurology, neurosurgery, and ophthalmology teams.
Repeated lumbar punctures are now rarely used as a long-term treatment due to rapid reaccumulation of CSF.
Some individuals have all the classic symptoms of IIH—especially headaches—but without any optic nerve swelling. This subtype, known as IIH without papilledema (IIHWOP), demands a slightly different treatment approach [2].
Consistent, structured follow-up is essential in IIH management. Most patients require:
These assessments guide decisions about medication adjustment, weight loss effectiveness, and the need for escalated care. Ongoing collaboration between neurology and ophthalmology is vital to protecting long-term vision.
Pediatric ophthalmology plays a crucial role in monitoring and managing IIH in children, ensuring early detection and specialized care for pediatric patients.
While lowering ICP can help reduce headaches, it's not always enough. Many patients continue to experience migraines or tension-type headaches, even after their pressure normalizes.
Treatment may include:
Idiopathic Intracranial Hypertension can feel overwhelming for patients and providers alike, but there's good news: for most, sustainable weight loss truly changes the game. Combined with medical therapy and ongoing monitoring, lifestyle changes offer a tangible path to better health, fewer symptoms, and long-term vision preservation. While surgery plays a role in some cases, it's weight management that remains the beating heart of effective IIH care.
[1] Mollan, S. P., Davies, B., Silver, N. C., Shaw, S., Mallucci, C. L., Wakerley, B. R., Krishnan, A., Chavda, S. V., Ramalingam, S., Edwards, J., Hemmings, K., Williamson, M., Burdon, M. A., Hassan-Smith, G., Digre, K., Liu, G. T., Jensen, R. H., & Sinclair, A. J. (2018). Idiopathic intracranial hypertension: consensus guidelines on management. Journal of neurology, neurosurgery, and psychiatry, 89(10), 1088–1100. https://doi.org/10.1136/jnnp-2017-317440
[2] Thurtell M. J. (2019). Idiopathic Intracranial Hypertension. Continuum (Minneapolis, Minn.), 25(5), 1289–1309. https://doi.org/10.1212/CON.0000000000000770
[3] Ko M. W. (2011). Idiopathic intracranial hypertension. Current treatment options in neurology, 13(1), 101–108. https://doi.org/10.1007/s11940-010-0101-x
[4] Kanagalingam, S., & Subramanian, P. S. (2018). Update on Idiopathic Intracranial Hypertension. Current treatment options in neurology, 20(7), 24. https://doi.org/10.1007/s11940-018-0512-7
[5] Celebisoy, N., Gökçay, F., Sirin, H., & Akyürekli, O. (2007). Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta neurologica Scandinavica, 116(5), 322–327. https://doi.org/10.1111/j.1600-0404.2007.00905.x
[6] Piper, R. J., Kalyvas, A. V., Young, A. M., Hughes, M. A., Jamjoom, A. A., & Fouyas, I. P. (2015). Interventions for idiopathic intracranial hypertension. The Cochrane database of systematic reviews, 2015(8), CD003434. https://doi.org/10.1002/14651858.CD003434.pub3
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Brain Navi Biotechnology's NaoTrac performs first surgeries in Spain
Brain Navi has officially landed in Spain! TAIPEI, Aug. 11, 2025 /PRNewswire/ -- Such an achievement has been made possible through the first of many collaborations with our valued partner, Palex Healthcare. This milestone has been reached not only thanks to Palex's solid reputation and deep experience in the Spanish medical market, but also due to the trust and commitment of their team. Brain Navi CEO Jerry Chen stated, "Brain Navi is proud to work alongside a partner that shares our vision of surgical innovation and desire to improve the well-being of patients continuously." At this year's SENEC Congress, Spain's leading annual event hosted by the Spanish Society of Neurosurgery, which gathers experts from across the country to share the latest scientific advances and clinical innovations in the field, Spanish neurosurgeons had the opportunity to witness NaoTrac, Brain Navi's neurosurgical navigation robot, in action. Alongside Palex, Brain Navi showcased its technology throughout the event. Surgeons from all around Spain expressed strong interest in NaoTrac's capabilities and potential applications in their hospitals. "Spain holds great promise as a hub for neurosurgical innovation," said Carles Calaf, Director of the Neurosciences Business Unit at Palex Healthcare. "At SENEC, we witnessed firsthand how strongly surgeons responded to the need for more intelligent, AI-powered tools in the OR. This aligns with our belief that technology like NaoTrac can genuinely enhance surgical precision and support clinical teams in delivering better outcomes. With Brain Navi as our partner, we are confident this is only the beginning of helping more hospitals — and more patients — across Spain." Just one week after the congress, the first NaoTrac system was installed in a Spanish hospital, where neurosurgeons, supported by Brain Navi and Palex teams, performed the country's first surgeries using the NaoTrac. The surgeons were highly impressed by NaoTrac's precision and intuitive design, highlighting its user-friendliness and value as a powerful asset in the Operating Room. "At Palex, our mission is to bring cutting-edge medical technology closer to those who need it most," said Eulàlia Llopis, General Manager of the Hospital Area at Palex. "Collaborating with Brain Navi reflects our commitment to supporting clinicians with solutions that truly make a difference — in precision, efficiency, and above all, patient care." For Brain Navi, this marks a major milestone in our global expansion, reinforcing the mission to improve patient outcomes through advanced medical technologies and to empower surgical teams with the best tools available. View original content to download multimedia: SOURCE Brain Navi Biotechnology Co., Ltd.
Yahoo
21 hours ago
- Yahoo
My Child Brought Home A Pink Princess Nightgown — Then Said 5 Words That Cracked Me Wide Open
As a psychiatrist, I thought I understood identity and development — until my daughter showed me who she was. I've spent years studying human development, trauma, mood disorders and anxiety. I trained at leading institutions, specialized in adult and women's mental health, and supported individuals across the gender spectrum. But nothing has taught me more about authenticity, courage and unconditional love than raising my transgender daughter. There was no dramatic declaration. She didn't stand up one day and say, 'I'm not a boy.' It unfolded slowly — like breadcrumbs gently guiding us home. She borrowed a friend's princess dress and didn't want to give it back. She cried after every haircut, gravitated toward sparkles and mermaids, adored strong, magical female characters, and always seemed out of place in the boys' section. Over time, she didn't need to say the words. We just knew. One night after a playdate, she slipped into a borrowed pink princess nightgown. She twirled, smiled and said, 'It's a little itchy … but I want to sleep in it. It makes me feel beautiful.' Hearing those last five words — 'it makes me feel beautiful' — cracked something open. I saw her — not just my child, but her truth. And I couldn't unsee it. She socially transitioned when she was 5. That meant we began using her chosen name and she/her pronouns. She wore the clothes she loved. She introduced herself as a girl. It wasn't about pushing an identity on her — it was about letting her finally exhale. And yes, I was scared. I worried she was too young and questioned whether she understood what she was saying. But when I stopped projecting my fear onto her, I realized the fear was mine — not hers. It came from everything I'd been taught and everything I thought I knew. As a psychiatrist, I knew gender identity was a natural part of life. But I wasn't trained to affirm it — especially when it defied expectations. We studied gender identity through a clinical, often pathological lens — under diagnoses like 'gender dysphoria.' The focus was on distress, not joy. On incongruence, not authenticity. We were taught in medical school how to label it, not how to understand it. No one told us that being transgender could be a radiant expression of self or that a child's desire to live as a different gender from the one they were assigned might come from clarity — not confusion. From peace — not pain. And here's something that became impossible to ignore: When a child says they're a boy or girl and it matches the sex they were assigned at birth, we don't question it. We accept it. We celebrate it. But when a child tells us something different — something unfamiliar — we panic. We look for pathology. That double standard reveals more about us than it does about them. The fear was intense, but I kept waiting, hoping things would make more sense. Ignoring it didn't help. I could see her slipping further away, and it broke me. Then one day, out of nowhere, she smiled. She was wearing that same itchy pink nightgown — and it was the first genuine smile I'd seen in what felt like forever. That moment changed everything. As a mom, I've listened, learned and connected with experts and other families on this journey. And as both a parent and a medical professional, I've sought out facts — not fear. Here's what I've found: Puberty blockers? Fully reversible. Cross-hormones? Prescribed with great care and only under close medical supervision — typically not until adolescence, following well-established feminizing and masculinizing hormone therapy protocols. Surgery for minors? Exceptionally rare. The Trevor Project's 2023 survey shows dramatically lower rates of suicide attempts among trans youth who feel affirmed. That's the kind of outcome every parent — and every policymaker — should be paying attention to. Today, our 8-year-old daughter is thriving. She's funny, creative and stubborn in the best way. She FaceTimes her friends, dances on TikTok, and loves makeup and skincare. Her friends accept her. Her teachers support her. And while some older family members were initially unsure — more out of fear than judgment — they came around with love. She is not confused. She is not broken. She is a girl who knows exactly who she is. But even as she thrives, the world around her grows more dangerous. Two major hospitals in California — including Children's Hospital Los Angeles — are backing away from gender-affirming care. Not because of new science but because of political fear: subpoenas, federal funding threats and media backlash. These rollbacks are happening in red states and progressive cities like Chicago, Washington, D.C., and Pittsburgh. Let's be clear: This isn't about protecting children. It's about controlling them. When trans youth are targeted, it's never just about them. Reproductive freedom, LGBTQ+ rights and bodily autonomy are all part of the same fight. And make no mistake: Decisions about our children's medical care should be made by parents, children and doctors — not by politicians stoking fear and ignoring science. Every primary medical associationin the United States supports gender-affirming care for youth. History won't forget this moment. And we don't have to wait to be ashamed later. We can act now. We can choose compassion over cruelty. Understanding over judgment. People ask me, 'What if she changes her mind?' My answer is simple: We love her as we always have. That's what parenting is — showing up with love, no matter what. However, most kids who socially transition don't change their minds. When they do, it's usually not because of regret, but because the world makes being themselves unbearably hard. My daughter is still the same tenderhearted child she's always been. But now she's free. Now she's whole. And every time I see her dancing, laughing or simply being herself, I think of that itchy pink nightgown — the one that taught me more about truth, courage and unconditional love than any medical degree ever could. If this story makes you uncomfortable, I invite you to sit with that. Let discomfort be the beginning — not the end — of your understanding. Trans kids don't need you to have all the answers. They need you to believe them. Because when we believe them, we give them the freedom to shine truly. Mollie Hart is a psychiatrist and mother whose writing explores identity, parenting and the quiet strength it takes to raise a child as they are. Do you have a compelling personal story you'd like to see published on HuffPost? Find out what we're looking for here and send us a pitch at pitch@ Related... I Came Out As Trans At 63. People Ask Me Lots Of Questions, But There's 1 That Scares Me Most. Trump Has Made Me Terrified For My Trans Son's Life, But There's 1 Thing I Won't Do To Save Him I'm Trans And A Puberty Blocker Saved My Life. Here's What I Want You To Know. Solve the daily Crossword
Yahoo
3 days ago
- Yahoo
Vycor Medical Releases Financial Results for the Three and Six Months Ended June 30, 2025
BOCA RATON, FL - August 8, 2025 (NEWMEDIAWIRE) - Vycor Medical, Inc. ("Vycor" or the "Company") (OTCQB-VYCO), today announced financial results for the three and six months ended June 30, 2025. The Company operates through two business units: Vycor Medical, which produces the ViewSite(TM) Brain Access System (VBAS) for neurosurgery; and NovaVision(R), a business in development which offers therapy programs to help patients recover from visual disorders after stroke or brain injury. Company Highlights The Vycor Medical division revenues for the three and six months ended June 30, 2025 increased by 24% and 28%, respectively, most of the increase being from growth in international markets. Operating profit for the three and six months ended June 30, 2025 was $51,146 and $38,340, respectively, and non-GAAP operating profit for the three and six months ended June 30, 2025 was $84,481 and $106,944, respectively, all substantial increases over the 2024 periods. Vycor entered into new distribution agreements for France and Spain during the six months ended June 30, 2025, two important markets targeted for international expansion. Two new clinical papers were published involving the ViewSite Brain Access System (VBAS) during the three months ended June 30, 2025 in addition to the three papers published during the first three months of the year, bringing the total published peer reviewed clinical papers to 48. The two studies published were systematic reviews of tubular retractors in general brain surgery and neuro-oncology surgery, respectively, and highlighted the clinical advantages of VBAS. A new clinical study on NovaVision's NeuroEyeCoach was published, comparing results from using the program at home or in a clinic. The study concluded that both home-based and clinic-based patients showed meaningful improvements with no significant differences in activities of daily living improvements, validating NeuroEyeCoach as an effective tool, whether used clinically or accessed remotely. This is an important study for the company given the significant drive in healthcare systems worldwide to access digital technologies in home settings. Financial Results For the three months ended June 30, 2025, the Company reported revenue of $496,353, an increase of $90,075 (or 22%) over the same period in 2024. The Vycor Medical division (VBAS) generated revenue of $481,788, an increase of $94,539 (or 24%) over the same period in 2024, most of the increase being from growth in international markets. The gross profit margin for 2025 was 83% versus 91% in 2024, with the lower gross margin in 2025 attributable to validation and shipping costs of new production as well as geographical sales mix. The NovaVision division, which remains in development, generated revenues of $14,565 for the three months ended June 30, 2025, versus $19,029 in 2024, and gross margin of 93%, compared to 95% for 2024. For the six months ended June 30, 2025, the Company reported revenue of $932,731, an increase of $189,485 (or 25%) over the same period in 2024. The Vycor Medical division (VBAS) generated revenue of $900,308, an increase of $194,501 (or 28%) over the same period in 2024, most of the increase being from growth in international markets. The gross profit margin for 2025 was 83% versus 90% in 2024, with the lower gross margin in 2025 attributable to validation and shipping costs of new production as well as sales mix. The NovaVision division, which remains in development, generated revenues of $32,423 for the six months ended June 30, 2025, versus $37,439 in 2024, and gross margin of 94%, compared to 93% for 2024. Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenue: Vycor Medical $481,788 $387,249 $900,308 $705,807 NovaVision 14,565 19,029 32,423 37,439 $496,353 $406,278 $932,731 $743,246 Gross Profit Vycor Medical $401,783 $352,963 $743,581 $636,039 NovaVision 13,488 18,152 30,224 35,038 $415,271 $371,115 $773,805 $671,077 For the three months ended June 30, 2025 the Company reported non-GAAP Cash Operating Expenses of $330,790 compared to $339,256 in 2024 and non-GAAP Operating Profit of $84,481 compared to $31,859 in 2024. For the six months ended June 30, 2025 the Company reported non-GAAP Cash Operating Expenses of $666,861 compared to $630,766 in 2024 and non-GAAP Operating Profit of $106,944 compared to $40,311 in 2024. Reconciliation of Non-GAAP Information Management uses certain non-GAAP financial measures (including non-GAAP operating expenses and non-GAAP net loss and loss per share), which exclude non-cash depreciation of purchased assets and non-cash stock-based compensation. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company's current and future continuing operations. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures. Three months ended June 30, 2025 On a GAAP basis the Company reported Operating Expenses of $364,125, an operating profit of $51,146, a net income of $23,887 and net income of $0.00 per share. Vycor's GAAP operating costs include non-cash depreciation of purchased assets ($15,021) and non-cash stock compensation charges ($18,314). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release. On a non-GAAP basis, taking into account these adjustments, operating expenses were $330,790, non-GAAP operating profit was $84,481, and non-GAAP net income was $57,222 or $0.00 per share. Six months ended June 30, 2025 On a GAAP basis the Company reported Operating Expenses of $735,465, an operating profit of $38,340, a net loss of $176,861 and a loss of $0.01 per share. Vycor's GAAP operating costs include non-cash depreciation of purchased assets ($31,975) and non-cash stock compensation charges ($36,629). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release. On a non-GAAP basis, taking into account these adjustments, operating expenses were $666,861, non-GAAP operating profit was $106,944, and non-GAAP net loss was $108,257 or $0.00 per share. VYCOR MEDICAL, Statements of Comprehensive Loss(unaudited) For the three months ended June 30, For the six months ended June 30, 2025 2024 2025 2024 Revenue $496,353 $406,278 $932,731 $743,246 Cost of Goods Sold 81,082 35,163 158,926 72,169 Gross Profit 415,271 371,115 773,805 671,077 Operating Expenses: Research and development 4,201 2,263 9,963 2,263 Depreciation and amortization 14,881 14,881 29,761 29,761 Selling, general and administrative 345,043 337,793 695,741 632,407 Total Operating Expenses 364,125 354,937 735,465 664,431 Operating income 51,146 16,178 38,340 6,646 Other Income (Expense) Interest expense: Related Party (12,572) (12,841) (25,142) (24,872) Interest expense: Other (12,862) (13,327) (26,001) (26,665) Other income 4,544 Gain (loss) on foreign currency exchange 1 1 2 (149) Total Other Income (Expense) (25,433) (26,167) (51,141) (47,142) Income (Loss) Before Provision for Income Taxes 25,713 (9,989) (12,801) (40,496) Provision for income taxes - - - - Net Income (Loss) from continuing operations 25,713 (9,989) (12,801) (40,496) Loss from discontinued operations, net of tax (1,826) (49) (1,875) (150) Net Income (Loss) 23,887 (10,038) (14,676) (40,646) Preferred stock dividends - - (162,185) (162,185) Net Income (Loss) Available to Common Stockholders $23,887 ($10,038) ($176,861) ($202,831) Other Comprehensive Income (Loss) Foreign Currency Translation Adjustment - - - - Comprehensive Income (Loss) 23,887 (10,038) ($14,676) ($40,646) Income (Loss) Per Share - basic and diluted Income (Loss) from continuing operations $0.00 ($0.00) ($0.01) ($0.01) Loss from discontinued operations ($0.00) ($0.00) ($0.00) ($0.00) Income (Loss) available to common stockholders $0.00 ($0.00) ($0.01) ($0.01) Weighted Average Number of Shares Outstanding Basic 33,372,796 32,628,835 33,372,796 32,628,835 Weighted Average Number of Shares Outstanding Basic 38,667,862 32,628,835 33,372,796 32,628,835 VYCOR MEDICAL, Reconciliation of Operating Loss and Net Loss(unaudited) For the three months ended For the six months ended June 30, June 30, 2025 2024 2025 2024 GAAP Operating Expenses 364,125 354,937 735,465 664,431 Non-cash depreciation of purchased assets (1) (15,021) (15,681) (31,131) (31,301) Non-cash stock-based compensation (2) (18,314) - (36,629) (2,364) Total Non-GAAP Operating Expense Adjustments (33,335) (15,681) (67,760) (33,665) Non-GAAP Cash Operating Expenses $330,790 $339,256 $667,705 $630,766 GAAP Operating Profit (Loss) 51,146 16,178 38,340 6,646 Non-GAAP Operating Expense Adjustments, as above 33,335 15,681 67,760 33,665 Non-GAAP Operating Profit $84,481 $31,859 $106,100 $40,311 GAAP Net Income (Loss) available to common shareholders $23,887 $(10,038) $(176,861) $(202,831) Non-GAAP Operating Expense Adjustments, as above 33,335 15,681 67,760 33,665 Non-GAAP Net Income (Loss) available to common stockholders $57,222 $5,643 $(109,101) $(169,166) Non-GAAP Income (Loss) Per Share basic and diluted $0.00 $0.00 $(0.00) $(0.01) Weighted Average Number of Shares Outstanding Basic 33,372,796 32,628,835 33,372,796 32,628,835 Weighted Average Number of Shares Outstanding Diluted 38,667,862 32,628,835 33,372,796 32,628,835 (1) Non-Cash depreciation of purchased assetsThese are non-cash charges related to assets which can be impacted by the timing and magnitude of acquisitions. We consider our operating results without these charges when evaluating our ongoing costs and performance and therefore exclude such charges when presenting non-GAAP financial measures. (2) Non-Cash Stock-based compensation expense consists of expense relating to stock-based compensation issued to employees, outside directors and non-employees including stock options, restricted common stock, and warrants. Because of varying available valuation methodologies, subjective assumptions and the fact that these amounts vary in size and timing, we believe that the exclusion of stock-based compensation expense allows for a more accurate comparison of our financial results to previous periods. In addition, we believe it is useful to investors to understand the specific impact of stock-based compensation expenses on our operating results. About Vycor Medical, Inc. With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a publicly traded company (OTCQB: VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared or registered medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach. Vycor Medical's FDA-cleared ViewSite(TM) Brain Access System (VBAS) a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system has been approved and used in over 300 hospitals in the US and in numerous countries internationally. VBAS is protected by 46 issued and 11 pending patents and has been validated through over 45 peer-reviewed studies. These studies demonstrate that use of VBAS results in: less brain tissue damage; less invasive procedure; improved access and better visibility; and reduced operating and recovery time. For an overview of Vycor Medical's VBAS see VBAS Video. NovaVision provides a suite of clinically supported vision rehabilitation therapies aimed at helping patients recover from visual impairments caused by stroke or other brain injury. The Visual Restoration Therapy (VRT) is the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage, making it a unique and important option for patients seeking to regain lost visual capabilities. The complementary NeuroEyeCoach program, clinically supported by a 296-patient study (the largest to date in the neuro visual space), enables dramatic improvements in patients' ability to detect objects in the visual field by training them to make better eye movements with improvement in over 80% of patients. The NovaVision therapies, while showing a positive impact on these patients' lives, still require significant development to allow them to successfully address their market potential. For an overview of NovaVision see NovaVision Video. For the latest information on the company, including media and other coverage, and to learn more, please go online at or in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law. Investor Relations Contacts: B2i Digital:David ShapiroChief Executive OfficerB2i Digital, Officedavid@ Vycor Medical, Inc. Contacts: 951 Broken Sound Parkway, Suite 320Boca Raton, FL. 33487(561) 558-2020info@ LinkedIn:
